Drug Profile
AG 67650
Alternative Names: AG-67650Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator AP Biosciences
- Developer Allgenesis Biotherapeutics
- Class Bispecific antibodies; Eye disorder therapies; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Wet age-related macular degeneration
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Wet-age-related-macular-degeneration in Taiwan
- 01 Aug 2017 Allgenesis Biotherapeutics in-licenses AG 67650 from AP Biosciences before August 2017 (Allgenesis Biotherapeutics website, August 2017)
- 01 Aug 2017 Preclinical trials in Wet age-related macular degeneration in Taiwan before August 2017 (Allgenesis Biotherapeutics website, August 2017)